Clinical trials: Impaired Driving
Cannabis Intoxication
The Impact and Detection of Driving Impairments Associated With Acute Cannabis Smoking
This study was authorized by the California Legislature (Assembly Bill 266, the Medical Marijuana Regulation and Safety Act to help with detection of driving under the influence of cannabis.
- Trial name
- NCT02849587
- Testing
- Cannabis
- Where
- United States
- Volunteers
- 199 people, healthy volunteers welcome
- Sponsor
- University of California, San Diego
Driving Performance, Cognitive Impairment
The Effects of Cannabidiol on the Driving Ability of Healthy Adults
A randomized, parallel-group, double-blind, exploratory two-arm trial to assess the effects of CBD on driving ability along with changes in psychological status (i.e. mood, drowsiness, sedation) and cognitive function.
- Conditions
- Driving Performance, Cognitive Impairment, Sedation Complication, Mood
- Trial name
- NCT04590495
- Testing
- 300 mg Cannabidiol (CBD) oil
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- West Virginia University
Psychomotor Impairment
Combined Alcohol and Cannabis Effects on Skills of Young Drivers
Alcohol and cannabis are the two most widely used substances of abuse in the world and are the psychoactive substances most often found in seriously and fatally injured drivers.
- Trial name
- NCT03106363
- Testing
- alcohol, delta 9 tetrahydrocannabinol
- Where
- Canada
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
Driving Impaired
Driving Simulation to Assess Non-Sedative Effects of Tolperisone
This is a randomized blinded study to assess the sedative effect of 150 mg TID tolperisone and 10 mg TID cyclobenzaprine compared to placebo on simulated driving performance and cognitive functioning in healthy adult volunteers.
- Trial name
- NCT03353922
- Testing
- Cyclobenzaprine 10 Mg Oral Tablet
- Where
- 2 sites in United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Neurana Pharmaceuticals, Inc.
Substance-Related Disorders
Preventing Impaired Driving Among Adolescents
The primary goal of this project is to evaluate the efficacy of webCHAT, a single-session web-intervention, on reducing impaired driving among adolescents receiving behind-the-wheel training at driver education programs.
- Trial name
- webCHAT (NCT04959461)
- Testing
- webCHAT, Usual Care
- Where
- 2 sites in United States
- Volunteers
- 198 people, healthy volunteers welcome
- Sponsor
- Stanford University
Alcohol-Impaired Driving
An Interactive Text-Message Based Brief Intervention to Reduce Substance-Impaired Driving Among College Students
Substance-Impaired Driving among college students remains a significant public health concern and may be the single riskiest substance-related outcome among young adults.
- Trial name
- NCT03496129
- Testing
- Personalized feedback, Personalized feedback and text messages, Information Only
- Where
- United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Western Kentucky University
Shift-Work Sleep Disorder, Insomnia
Fire Fighter Fatigue Management Program: Operation Healthy Sleep
Firefighters work some of the most demanding schedules known under highly stressful and demanding conditions. The need to work frequent extended shifts and long work weeks leads to acute and chronic partial sleep deprivation as…
- Conditions
- Shift-Work Sleep Disorder, Insomnia, Restless Leg Syndrome, Obstructive Sleep Apnea
- Trial name
- NCT01988129
- Testing
- Sleep disorders education and screening
- Where
- United States
- Volunteers
- 1,189 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Underage Drinking, Driving Under the Influence
Project MADD - NIH Underage DUI and Ride
Project MADD was designed to attempt to curb the alarming trends related to drunk driving and to move the field forward by testing a brief parent-intervention's ability to change adolescents' drinking, impaired driving, and…
- Conditions
- Underage Drinking, Driving Under the Influence, Drinking, Teen
- Trial name
- NCT03506880
- Testing
- MADD Materials, Surgeon General Materials
- Where
- United States
- Volunteers
- 2,352 people, healthy volunteers welcome
- Sponsor
- Penn State University
Alzheimer's Disease
Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease
The purpose of the study is to determine whether memantine delays the progression of driving impairment in patients with mild Alzheimer's Disease (AD).
- Trial name
- NCT00476008
- Testing
- Memantine
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Florida Atlantic University
Psychomotor Impairment
Cannabis Effects on Driving-related Skills of Young Drivers
Motor vehicle collisions are the leading cause of death for young people. The investigators have recently found that driving after using cannabis is more common among young Canadian drivers than driving after drinking.
- Trial name
- NCT01592409
- Testing
- delta-9-tetrahydrocannabinol
- Where
- Canada
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
Driving Under the Influence
Alcohol Impaired Driving in the Natural Environment
This is a pilot study to set up a larger investigation examining predictors of the decision to drive after consuming alcohol. All participants will carry a study provided smartphone and breathalyzer device for the 2 week period…
- Trial name
- NCT03503396
- Testing
- BAC Driving Feedback/Warning, No Feedback
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- University of Missouri-Columbia
Active Ethanol and Active Iomazenil, Active Ethanol and Placebo Iomazenil
Ability of Partial Inverse Agonist, Iomazenil, to Block Ethanol Effects in Humans
Alcohol is abused commonly, but there is no remedy for alcohol intoxication. This project is looking at the substance iomazenil and its effect on alcohol intoxication and alcohol's effects on driving using a driving simulator.
- Conditions
- Active Ethanol and Active Iomazenil, Active Ethanol and Placebo Iomazenil, Placebo Ethanol and Active Iomazenil, Placebo Ethanol and Placebo Iomazenil
- Trial name
- NCT01590277
- Testing
- Active Ethanol, Active Iomazenil
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Cognitive Impairment
Assess the Effect of Metaxalone 640 mg (M640) Compared to Tizanidine 8 mg on Truck Driving Ability and Cognition
Every participant will receive active study drug and one (1 )comparator, in two (2) stages, one after the other. Each drug will be taken one (1) time after a high fat meal.
- Trial name
- NCT06382662
- Testing
- metaxalone m640 mg, tizanidine 8mg
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Primus Pharmaceuticals
Psychomotor Impairment
Sedative-Anxiolytic Effects on Simulated Driving Performance
This study evaluates the effect of anxiety drugs taken at night on the ability to drive a car the next day. Participants will receive alprazolam, placebo, or zolpidem at night before bed or in the morning before using a driving…
- Trial name
- NCT03297944
- Testing
- Alprazolam 2mg (2ALP/PLC), Alprazolam 1mg (1ALP/PLC), Alprazolam 0.5mg (0.5ALP/PLC)
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Marion Coe
Alcohol Consumption
Vivitrol for Reducing Driving While Impaired Behavior Among Repeat Offenders
The purpose of this study is to determine whether Vivitrol is effective at reducing attempts to drive after drinking among repeat driving while intoxicated (DWI) offenders with Ignition Interlock devices.
- Trial name
- NCT00537745
- Testing
- Vivitrol (Medication Therapy), Medication Management Therapy
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Pacific Institute for Research and Evaluation
Cognitive Measures, Driving Simulator Performance
Phenytoin and Driving Safety: A Randomized, Controlled Cross-Over Study
Automobile driving is a crucial aspect of everyday life, yet vehicular crashes represent a serious public health problem. Patients with epilepsy are at elevated risk for automobile crashes, causing great personal suffering and…
- Trial name
- NCT00581893
- Testing
- Phenytoin
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Iowa
Driving Behavior, Driving Under the Influence
Validation of the Drug Impaired Driving Scenario (DIDS) on the CRCDS-miniSim
Subjects will participate in a 4-visit study protocol at the National Advanced Driving Simulator, part of the University of Iowa, in which they will be asked to complete assorted questionnaires, computerized cognitive tasks, and…
- Trial name
- PDID (NCT04970342)
- Testing
- 0.75 mg Alprazolam Capsule, Cannabis (6.18% THC / <0.025% CBD), Cannabis (0%/ THC / 0% CBD)
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Timothy L. Brown
Driving Impaired
Evaluation of an Interactive Mobile Phone-Based Brief Intervention to Reduce Substance-Impaired Driving
Substance-Impaired Driving among emerging adults remains a significant public health concern and may be the single riskiest substance-related outcome among young adults.
- Trial name
- NCT05537116
- Testing
- Personalized feedback, Personalized feedback and text messages, Information Only
- Where
- United States
- Volunteers
- 149 people, healthy volunteers welcome
- Sponsor
- Western Kentucky University
Choroidal Neovascularization Secondary to Pathologic Myopia
A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia.
The primary objective of the study was to investigate current criteria driving re-treatment in patients affected by Choroidal Neovascularization (CNV) secondary to Pathologic Myopia (PM) and experiencing a relapse of the disease…
- Trial name
- OLIMPIC (NCT02034006)
- Testing
- Ranibizumab
- Where
- 31 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Novartis Pharmaceuticals